94th Vifor Pharma Group Annual General Meeting

Rhea-AI Summary

At the 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions by the Board of Directors, including the Annual Financial Statements and the Remuneration Report. A dividend of CHF 2.00 was approved, payable from May 3, 2022. The meeting re-elected all current Board members, including Chairman Jacques Theurillat, and conditionally elected new members to the Board, effective upon settlement of CSL Behring AG's tender offer on January 18, 2022.

Positive

• Approved dividend of CHF 2.00, enhancing shareholder returns.
• All Board members re-elected, ensuring continuity in governance.

Negative

• None.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

• Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions
• Dividend of CHF 2.00 approved
• All Board members re-elected and Conditional Board of Directors appointed, effective as from the date of the settlement of the tender offer by CSL Behring AG

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News:

At today’s 94^th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.

Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd. and the consolidated Financial Statements of Vifor Pharma for 2021 by a large majority, as well as the 2021 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2021. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 3 May 2022 on.

Re-election of Board of Directors
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Hon. Dr. Michel Burnier, Dr. Romeo Cerutti, Dr. Alexandre LeBeaut, Dr. Sue Mahony, Åsa Riisberg and Kim Stratton in office, as well as Dr. Sue Mahony (Chair), Prof. Hon. Dr. Michel Burnier and Dr. Romeo Cerutti to the Remuneration Committee.

Conditional new elections to the Board, effective as from settlement date
In addition, the Annual General Meeting conditionally elected Paul McKenzie (elected Chairman), Greg Boss, John Levy, Joy Linton, Markus Stämpfli and Elizabeth Walker as new members of the Board of Directors, to become effective as from the date of settlement under the terms of the tender offer of CSL Behring AG as of 18 January 2022. Greg Boss, Joy Linton and Elizabeth Walker have been conditionally elected to the Remuneration Committee.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005779/en/

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

Source: Vifor Pharma Group

FAQ

What dividend was approved at Vifor Pharma's Annual General Meeting?

A dividend of CHF 2.00 was approved to be paid from May 3, 2022.

Who was re-elected to Vifor Pharma's Board of Directors?

All current Board members, including Chairman Jacques Theurillat, were re-elected.

What was the date for the conditional elections to the Board of Vifor Pharma?

The conditional elections will be effective from January 18, 2022, upon the settlement of the tender offer by CSL Behring AG.

Did Vifor Pharma's shareholders approve the Annual Financial Statements?

Yes, shareholders approved the Annual Financial Statements by a large majority at the meeting.

What is Vifor Pharma's focus as a global pharmaceuticals company?

Vifor Pharma aims to become a leader in iron deficiency and nephrology, providing innovative patient-focused solutions.